Suppr超能文献

证据表明,蛋白 C 水平低会导致肝硬化中的促凝失衡。

Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis.

机构信息

Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milano, Italy.

出版信息

J Hepatol. 2013 Aug;59(2):265-70. doi: 10.1016/j.jhep.2013.03.036. Epub 2013 Apr 11.

Abstract

BACKGROUND & AIMS: Cirrhosis is associated with a plasmatic procoagulant imbalance, detected in vitro by thrombin generation tests performed in the presence vs. absence of such activators of protein C as thrombomodulin or Protac. This imbalance is thought to be due to decreased protein C and increased factor VIII, but this has never been directly demonstrated. To test this hypothesis we analyzed plasma from 50 patients with cirrhosis before and after in vitro addition of purified protein C meant to restore normal levels.

METHODS

Results for two thrombin generation assays were expressed as ratios of endogenous thrombin potential (ETP) with-to-without thrombomodulin or as Protac-induced coagulation inhibition (PICI%). By definition, high ETP ratios or low PICI% reflect a resistance to the anticoagulant action of thrombomodulin or Protac, respectively, and can be taken as indexes of in vitro procoagulant imbalance.

RESULTS

The median (range) protein C level before addition was 40% (4-101%) and increased to 156% (110-305) after addition (p<0.001). The procoagulant imbalance, which was high before protein C addition [ETP ratio=0.83 (0.44-1.00)], was reduced after addition [ETP ratio=0.60 (0.14-0.84)], p<0.001. ETP-ratios were inversely correlated with protein C activity (rho=-0.46, p<0.001). Similar results were obtained with the Protac assay.

CONCLUSIONS

The results provide evidence that low protein C contributes to the procoagulant imbalance in plasma from patients with cirrhosis. The findings may have clinical implications for the treatment or prophylaxis of thrombosis in these patients.

摘要

背景与目的

肝硬化与凝血酶生成试验检测到的血浆促凝失衡有关,该试验在存在或不存在蛋白 C 激活剂如血栓调节蛋白或 Protac 的情况下进行。这种失衡被认为是由于蛋白 C 减少和因子 VIII 增加所致,但这从未被直接证明。为了验证这一假设,我们分析了 50 例肝硬化患者的血浆,这些血浆在体外添加了旨在恢复正常水平的纯化蛋白 C 前后。

方法

两种凝血酶生成试验的结果分别表示为有血栓调节蛋白或 Protac 时的内源性凝血酶潜能(ETP)与无血栓调节蛋白或 Protac 时的比值,或表示为 Protac 诱导的凝血抑制(PICI%)。根据定义,高 ETP 比值或低 PICI%分别反映了对血栓调节蛋白或 Protac 的抗凝作用的抵抗,可作为体外促凝失衡的指标。

结果

添加前的中位数(范围)蛋白 C 水平为 40%(4-101%),添加后增加至 156%(110-305)(p<0.001)。在添加蛋白 C 之前,促凝失衡较高[ETP 比值=0.83(0.44-1.00)],添加后降低[ETP 比值=0.60(0.14-0.84)],p<0.001。ETP 比值与蛋白 C 活性呈负相关(rho=-0.46,p<0.001)。Protac 检测也得到了类似的结果。

结论

这些结果提供了证据表明,低蛋白 C 导致肝硬化患者血浆中的促凝失衡。这些发现可能对这些患者的血栓形成治疗或预防具有临床意义。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验